Blog: MEDTECH ACQUISITION CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) – Marketscreener.com

Item 7.01 Regulation FD Disclosure.

On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation
(“MTAC”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)
with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary
of MTAC (“Merger Sub”), and TriSalus Life Sciences, Inc., a Delaware corporation
(“TriSalus”), pursuant to which, subject to the satisfaction or waiver of
certain conditions set forth therein, Merger Sub will merge with and into
TriSalus (the “Merger”), with TriSalus surviving the Merger as a wholly owned
subsidiary of MTAC, and with TriSalus’s equity holders receiving shares of MTAC
common stock (the transactions contemplated by the Merger Agreement and the
related ancillary agreements, the “Business Combination”). Upon consummation of
the Business Combination, MTAC will be renamed “TriSalus Life Sciences, Inc.”

On November 21, 2022, MTAC and TriSalus issued a joint press release and made
social media posts providing an update on its ongoing Pressure-Enabled Regional
Immuno-Oncology (“PERIO™”) 01 and 02 clinical studies for primary and metastatic
liver tumors. The press release and social media posts are furnished hereto as
Exhibit 99.1 and Exhibit 99.2, respectively.

Also, furnished as Exhibit 99.3 hereto and incorporated herein by reference is
an investor presentation providing an update on the PERIO™ 01 and 02 clinical
studies that may be used from time to time by MTAC and TriSalus in connection
with the Business Combination.

The information in this Item 7.01, including Exhibit 99.1, Exhibit 99.2 and
Exhibit 99.3, is furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to liabilities under that section, and shall not be
deemed to be incorporated by reference into the filings of MTAC under the
Securities Act or the Exchange Act, regardless of any general incorporation
language in such filings. This Current Report on Form 8-K will not be deemed an
admission as to the materiality of any information in this Item 7.01, including
Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3.

Changes and Additional Information in Connection with SEC Filing

MTAC intends to file a registration statement on Form S-4 (the “Registration
Statement”) that will include a proxy statement/prospectus of MTAC, that will be
both the proxy statement to be distributed to holders of MTAC’s common stock in
connection with its solicitation of proxies for the vote by MTAC’s stockholders
with respect to the Business Combination and other matters as may be described
in the Registration Statement, as well as the prospectus relating to the offer
and sale of the securities to be issued in the Business Combination. The
Registration Statement is not yet effective. The Registration Statement,
including the proxy statement/prospectus contained therein, when it is declared
effective by the U.S. Securities and Exchange Commission (the “SEC”), will
contain important information about the Business Combination and the other
matters to be voted upon at a meeting of MTAC’s stockholders to be held to
approve the Business Combination and other matters (the “Special Meeting”). MTAC
may also file other documents with the SEC regarding the Business Combination.
MTAC stockholders and other interested persons are advised to read, when
available, the Registration Statement, including the proxy statement/prospectus
contained therein, as well as any amendments or supplements thereto, because
they will contain important information about the Business Combination. When
available, the definitive proxy statement /prospectus will be mailed to MTAC
stockholders as of a record date to be established for voting on the Business
Combination and the other matters to be voted upon at the Special Meeting.







Participation in Solicitation


MTAC and TriSalus and their respective directors and executive officers, under
SEC rules, may be deemed to be participants in the solicitation of proxies of
MTAC’s stockholders in connection with the Business Combination. Investors and
security holders may obtain more detailed information regarding the names and
interests in the Business Combination of MTAC’s directors and officers in MTAC’s
filings with the SEC, including MTAC’s registration statement on Form S-1, which
was originally filed with the SEC on November 30, 2020, as amended, and MTAC’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed
with the SEC on March 2, 2022 (the “2021 Form 10-K”). To the extent that
holdings of MTAC’s securities have changed from the amounts reported in MTAC’s
2021 Form 10-K, such changes have been or will be reflected on Statements of
Change in Ownership on Form 4 filed with the SEC. Information regarding the
persons who may, under SEC rules, be deemed participants in the solicitation of
proxies from MTAC’s stockholders in connection with the Business Combination
will be set forth in the proxy statement/prospectus forming a part of the
Registration Statement. Investors and security holders of MTAC and TriSalus are
urged to carefully read in their entirety the proxy statement/prospectus and
other relevant documents that will be filed with the SEC, when they become
available, because they will contain important information about the Business
Combination.

Investors and security holders will be able to obtain free copies of the proxy
statement/prospectus and other documents containing important information about
MTAC and TriSalus through the website maintained by the SEC at http://www.sec.gov.
Copies of the documents filed with the SEC by MTAC can be obtained free of
charge by directing a written request to MedTech Acquisition Corporation at 48
Maple Avenue, Greenwich, CT 06830.

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR
DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY
PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING THEREOF OR THE ACCURACY OR
ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY
IS A CRIMINAL OFFENSE.



Use of Data


The data contained herein is derived from various internal and external sources.
Neither MTAC nor TriSalus has independently verified the accuracy or
completeness of the information derived from external sources. Any market data
in the communication involves a number of assumptions and limitations, and there
can be no guarantee as to the accuracy or reliability of such assumptions.
Further, no representation is made as to the reasonableness of the assumptions
made within or the accuracy or completeness of any projections or modeling or
any other information contained herein. Any data on past performance or modeling
contained herein is preliminary, subject to change and may not be indicative of
actual future performance. MTAC and TriSalus assume no obligation to update the
information in this communication.



Forward-Looking Statements


This Current Report on Form 8-K contains certain “forward-looking statements”
within the meaning of the United States federal securities laws regarding MTAC’s
or TriSalus’s expectations, hopes, beliefs, assumptions, intentions or
strategies regarding the future including, without limitation, statements
regarding: (i) the tolerability of SD-101 infusion with TriSalus’s TriNav
Infusion System, (ii) the potential of TriSalus’s proprietary Pressure-Enabled
Drug Delivery™ method to enable SD-101 to have broad immune effects in liver
tumors and eliminate myeloid-delivered suppressor cells, (iii) expectations for
continuing program development and potential outcomes, (iv) TriSalus’s ability
to compete with other companies, and (v) expectations for topline data and
regulatory approval. These forward-looking statements generally are identified
by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “strive,” “would,” “will” and similar expressions or the
negative or other variations of such statements. These statements are
predictions, projections and other statements about future events that are based
on various assumptions, whether or not identified in this Current Report on Form
8-K and on the current expectations of MTAC’s and TriSalus’s respective
managements and are not predictions of actual performance and, as a result, are
subject to risks and uncertainties.

Many factors could cause actual results or developments to differ materially
from those expressed or implied by such forward-looking statements, including
but not limited to: (i) the risk that the Business Combination may not be
completed in a timely manner or at all, which may adversely affect the price of
MTAC’s securities; (ii) the risk that the Business Combination may not be
completed by MTAC’s business combination deadline and the potential failure to
obtain an extension of the business combination deadline; (iii) the failure to
satisfy the conditions to the consummation of the Business Combination,
including the approval of the Merger Agreement by the stockholders of MTAC, the
satisfaction of the minimum cash amount following any redemptions by MTAC’s
public stockholders, and the receipt of certain governmental and regulatory
approvals, including reimbursement approval; (iv) the lack of a third-party
valuation in determining whether or not to pursue the Business Combination; (v)
the occurrence of any event, change or other circumstance that could give rise
to the termination of the Merger Agreement; (vi) the receipt of an unsolicited
offer from another party for an alternative transaction that could interfere
with the Business Combination; (vii) the effect of the announcement or pendency
of the Business Combination on TriSalus’s business relationships, operating
results and business generally; (viii) risks that the Business Combination
disrupts current plans and operations of TriSalus; (ix) the outcome of any legal
proceedings that may be instituted against TriSalus or MTAC related to the
Merger Agreement or the Business Combination; (x) the ability to maintain the
listing of MTAC’s securities on the Nasdaq; (xi) changes in business, market,
financial, political and legal conditions; (xii) unfavorable changes in the
reimbursement environment for TriSalus’s products; (xiii) TriSalus’s product
candidates not achieving success in preclinical or clinical trials or not being
able to obtain regulatory approval, either on a timely basis or at all or
subject to any conditions that negatively impact TriSalus’s ability to
commercialize the applicable product candidates; (xiv) TriSalus being unable to
continue to grow TriNav sales; (xv) the size of the addressable markets for
TriNav and TriSalus’s product candidates, if successfully developed and approved
by the applicable regulatory authorities, being less than TriSalus estimates;
(xvi) TriSalus’s ability to successfully commercialize any product candidates
that it successfully develops and that are approved by applicable regulatory
authorities; (xvii) TriSalus’s ability to continue to fund preclinical and
clinical trials for its product candidates; (xviii) TriSalus’s ability to
partner with other companies; (xix) future economic and market conditions; (xx)
the development, effects and enforcement of laws and regulations affecting
TriSalus’s business or industry; (xxi) TriSalus’s ability to manage future
growth; (xxii) TriSalus’s ability to maintain and grow its market share; (xxiii)
the effects of competition on TriSalus’s business; (xxiv) the ability of MTAC or
the combined company to raise additional financing in connection with the
Business Combination or to finance its operations in the future; (xxv) the
ability to implement business plans, forecasts and other expectations after the
completion of the Business Combination, and identify and realize additional
opportunities; (xxvi) costs related to the Business Combination; and (xxvii) the
failure to realize the anticipated benefits of the Business Combination or to
realize estimated pro forma results and the underlying assumptions, including
with respect to estimated stockholder redemptions. The foregoing list of factors
is not exclusive.

You should carefully consider the foregoing factors and other risks and
uncertainties described in the “Risk Factors” section of MTAC’s 2021 Form 10-K,
the preliminary proxy statement/prospectus on Form S-4 relating to the Business
Combination, which is expected to be filed by MTAC with the SEC and other
documents filed by MTAC from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could cause actual
events and results to differ materially from those expressed or implied in the
forward-looking statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and none of MTAC, TriSalus, or any of their
respective representatives assume any obligation and do not intend to update or
revise these forward-looking statements, whether as a result of new information,
future events, or otherwise. None of MTAC, TriSalus, or any of their respective
representatives gives any assurance that either MTAC or TriSalus will achieve
its expectations.




No Offer or Solicitation



This Current Report on Form 8-K shall not constitute an offer to sell, a
solicitation of an offer to buy or a recommendation to purchase any securities,
or the solicitation of any proxy, vote, consent or approval in any jurisdiction
in connection with the Business Combination, nor shall there be any offer,
solicitation or sale of securities in any jurisdiction in which the offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such jurisdictions. This
communication is restricted by law; it is not intended for distribution to, or
use by any person in, any jurisdiction where such distribution or use would be
contrary to local law or regulation. No offering of securities shall be made
except by means of a prospectus meeting the requirements of Section 10 of the
U.S. Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No.   Description
  99.1          Press Release, dated November 21, 2022.
  99.2          Social Media Posts.
  99.3          Investor Presentation.
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s